Therapeutic | Emapalumab |
Target | IFNG |
Heavy Chain | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGSSGWYVPHWFDPWGQGTLVTVSS |
Light Chain | NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDGSNRWMFGGGTKLTVL |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | NFD |
Recorded Developmental Technology | na |
INN Year Proposed | 2016 |
INN Year Recommended | 2017 |
Companies Involved | NovImmune SA, Swedish Orphan Biovitrum |
Conditions Approved | Haemophagocytic lymphohistiocytosis |
Conditions Active | na |
Conditions Discontinued | na |
Notes |